+- Dividend Growth Forum (http://DividendGrowthForum.com)
+-- Forum: Dividend Growth Investing (http://DividendGrowthForum.com/forumdisplay.php?fid=15)
+--- Forum: Individual Dividend Growth Stocks (http://DividendGrowthForum.com/forumdisplay.php?fid=35)
+--- Thread: Top 2017 Picks (/showthread.php?tid=1630)
Pages:
1
2
RE: Top 2017 Picks - Roadmap2Retire - 01-03-2017
Thanks for participating. Here is the post with all the Top Investment Picks for 2017
http://roadmap2retire.com/2017/01/top-investment-picks-2017/
Good luck to all
RE: Top 2017 Picks - Kerim - 01-03-2017
For those of you picking GILD, can you share a few thoughts as to why the valuation is so low right now? Why is the market sour on it, and why is that perspective not accurate?
RE: Top 2017 Picks - Rasec - 01-03-2017
(01-03-2017, 01:04 PM)Kerim Wrote: For those of you picking GILD, can you share a few thoughts as to why the valuation is so low right now? Why is the market sour on it, and why is that perspective not accurate?
There are plenty of sound opinions out there which detail all aspects but in short, more competition from Merck and Abbvie, some patents on their top drugs going out of protection in the next couple of years, reduction in sales and sales guidance in 2016 vs 2015 and lastly some backlash on the exorbitant price on their HCV drugs (more PR than anything else).
IMHO, it justified a price correction in 2016, but not a P/E of 6.
RE: Top 2017 Picks - EricL - 01-03-2017
(01-03-2017, 01:04 PM)Kerim Wrote: For those of you picking GILD, can you share a few thoughts as to why the valuation is so low right now? Why is the market sour on it, and why is that perspective not accurate?
I think GILD has been caught up in a bad combo of questions about growth in its HCV business along with general dislike of the pharma sector due to concerns about legislative efforts to control prices by congress. The health care sector was one of the few in the market to see negative returns in 2016, if sentiment changes that alone will help GILD.
Also, while I don't see much growth going forward with the HCV business, HIV does have growth, which should mitigate losses. They also have a few drugs in trials that could provide future diversification and growth.
Basically to me it just boils down to the company trading at less than 7 times forward earnings and just 5.5 times cash flow. Value trap or not, it is generating huge volumes of cash, which they will eventually put to use to impact shares in a positive way.
It wouldn't surprise me at all to see GILD near $100 by the end of the year. Which would still have it trading for less than 10X earnings, and it would still be cheap compared to the rest of the market.
Of course, I've been wrong before...
RE: Top 2017 Picks - Kerim - 01-03-2017
Thanks guys. I've been tempted by GILD before, but it is far from my wheelhouse, and I'm determined to make safer plays than I have in the past. So not sure whether or how GILD would fit, but it does seem tempting enough to follow a bit more closely at least.
RE: Top 2017 Picks - divmenow - 01-03-2017
I have to put MDT on this list. It's been one of the best performers over the last 5+ years. Buy the good ones when there out of favor. Pays nice 2.4% dividend as well. Near a 52 week low. Buy it!!